MILWAUKEE--(BUSINESS WIRE)--BloodCenter of Wisconsin’s Diagnostic Laboratories today announced that it is the first laboratory in the United States to develop and offer a genetic test, known as “CEBPA Mutation Analysis,” for inherited acute myeloid leukemia (AML). AML is the second most common form of leukemia.
